| Followers | 16 |
| Posts | 1804 |
| Boards Moderated | 0 |
| Alias Born | 07/21/2013 |
Monday, November 17, 2025 7:09:38 AM
Maybe we need to reframe our expectations.
Our science is cutting edge and importantly, as falconer has pointed out, it's in the history books.
We're a wonderful buyout candidate.
I've lost count of the number of stupid acquisitions large companies in all industries have made in my lifetime.
That someone wouldn't take a shot at a daily AZ pill makes little sense to me.
Same goes for a partner.
It would so cool to go it alone, but partnering is a recognized path to shareholders value.
I don't have any problem with a so-so deal for A2-73 if it fuels the A3-71 train.
A Japanese partner intrigues me that way.
We could run that last Rett pediatric trial (with minimal dilution?) which would keep us in the game for years although that pushes everything else out in time.
We know almost nothing about the schizophrenia trial results but it's a big market and a possible wild card for us.
A3-71 really intrigues me. What if it's better than A2-73?
How would a company deal with the decision of which horse to ride and how hard?
My best guess is we go through the EMA process, dragging our feet as usual in regard to doing anything else.
Our science is cutting edge and importantly, as falconer has pointed out, it's in the history books.
We're a wonderful buyout candidate.
I've lost count of the number of stupid acquisitions large companies in all industries have made in my lifetime.
That someone wouldn't take a shot at a daily AZ pill makes little sense to me.
Same goes for a partner.
It would so cool to go it alone, but partnering is a recognized path to shareholders value.
I don't have any problem with a so-so deal for A2-73 if it fuels the A3-71 train.
A Japanese partner intrigues me that way.
We could run that last Rett pediatric trial (with minimal dilution?) which would keep us in the game for years although that pushes everything else out in time.
We know almost nothing about the schizophrenia trial results but it's a big market and a possible wild card for us.
A3-71 really intrigues me. What if it's better than A2-73?
How would a company deal with the decision of which horse to ride and how hard?
My best guess is we go through the EMA process, dragging our feet as usual in regard to doing anything else.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
